Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.
Sixty-two patients with hypertension who were treated with a free combination of Slow Trasicor or Trasicor and Navidrex K were transferred to a fixed combination tablet, Trasidrex (slow oxprenolol 160 mg + cyclopenthiazide 0.25 mg). Blood pressure control was marginally improved and there was no  increase in side-effects.
D000328:Adult; D000368:Aged; D001794:Blood Pressure; D003518:Cyclopenthiazide / Q000008:administration & dosage* / Q000009:adverse effects; D004232:Diuretics; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000008:administration & dosage* / Q000009:adverse effects; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*
D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D010096:Oxprenolol; D003518:Cyclopenthiazide